Hospitalization for serious blood and skin disorders following co-trimoxazole

Br J Clin Pharmacol. 1997 Jun;43(6):649-51. doi: 10.1046/j.1365-2125.1997.00590.x.


Aims: To quantify the risk of serious blood and skin disorders requiring hospitalization among otherwise healthy users of co-trimoxazole.

Methods: We conducted a population-based cohort study at Group Health Cooperative of Puget Sound (GHC).

Results: During the years 1987 to 1993 we found six cases of co-trimoxazole-associated blood disorders and three cases of co-trimoxazole-associated skin disorders yielding risks of 5.6/100,000 (95% CI 2.6-12.2) and 2.8/100,000 (95% CI 0.9-8.2) respectively. In all cases found there was prompt recovery after discontinuation of co-trimoxazole. We found no cases of toxic epidermal necrolysis.

Conclusions: We conclude that the risk of blood and skin disorders associated with the use of co-trimoxazole leading to hospitalization is low.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Infective Agents / adverse effects*
  • Child, Preschool
  • Cohort Studies
  • Erythema Multiforme / chemically induced
  • Female
  • Hematologic Diseases / chemically induced*
  • Hospitalization*
  • Humans
  • Leukopenia / chemically induced
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neutropenia / chemically induced
  • Pancytopenia / chemically induced
  • Product Surveillance, Postmarketing
  • Risk Assessment
  • Skin Diseases / chemically induced*
  • Stevens-Johnson Syndrome / chemically induced
  • Thrombocytopenia / chemically induced
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects*


  • Anti-Infective Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination